RxDoctor Payments Data

Bruce Cotugno, MD

Neurology · Washington, PANPI 1972580983

Payments from drug & device makers

$274,552in general payments, 2019–2025

Across 2,237 payments — averaging $122.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$65K
  • AbbVie$61K
  • Sanofi$38K
  • Biohaven Pharmaceuticals, Inc.$23K
  • EMD Serono, Inc.$19K
  • Genentech USA, Inc.$19K
  • plus $49K from 54 others

What the payments were for

  • Consulting fees$20,7438%
  • Speaking & faculty fees$197,39672%
  • Travel & lodging$7,3503%
  • Food & beverage$48,26318%
  • Education$8010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen142$64,892
AbbVie(2 entities)408$61,356
Sanofi101$38,198
Biohaven Pharmaceuticals, Inc.32$22,908
EMD Serono, Inc.99$18,971
Genentech USA, Inc.99$18,664
Biohaven Pharmaceutical Holding Company Ltd.22$15,079
UCB, Inc.142$2,589
Teva Pharmaceuticals USA, Inc.115$2,531
Livanova USA, Inc.16$2,518
Novartis170$2,345
E.r. Squibb & Sons, L.L.C.6$2,204
Genentech, Inc.3$1,798
SK Life Science, Inc.70$1,708
Acadia Pharmaceuticals Inc107$1,581
Jazz Pharmaceuticals Inc.27$1,157
MDD US Operations, LLC52$1,114
Acorda Therapeutics, Inc37$1,032
Eisai Inc.34$748
Johnson & Johnson20$741
Amgen(2 entities)26$712
Bristol Myers Squibb38$691
Neurocrine Biosciences, Inc.36$690
Avanir Pharmaceuticals, Inc.18$644
Lundbeck LLC25$633
Lilly USA, LLC26$629
Argenx US, Inc.27$619
Neurelis, Inc.26$615
Pfizer31$574
AstraZeneca(2 entities)18$549
Amneal Pharmaceuticals LLC31$540
Greenwich Biosciences, Inc.11$484
Otsuka America Pharmaceutical, Inc.15$477
Mallinckrodt Enterprises LLC4$366
TG Therapeutics, Inc.5$358
Kyowa Kirin, Inc.17$333
Sunovion Pharmaceuticals Inc.28$317
Tanabe Pharma America, Inc.13$303
Boston Scientific8$262
Impel Pharmaceuticals Inc.16$245
Alnylam Pharmaceuticals Inc.6$210
Supernus Pharmaceuticals, Inc.17$209
Adamas Pharmaceuticals, Inc.10$165
Mallinckrodt Hospital Products Inc.3$152
GE HealthCare10$134
CSL Behring2$128
Ipsen Biopharmaceuticals, Inc1$124
Sumitomo Pharma America, Inc.8$110
W. L. Gore & Associates, Inc.1$97
Arbor Pharmaceuticals, Inc.7$96
Collegium Pharmaceutical, Inc.4$84
GRT US Holding, Inc.5$84
Grifols USA, LLC4$82
Bausch Health US, LLC4$66
Currax Pharmaceuticals LLC5$66
Merz Pharmaceuticals, LLC3$64
Vertical Pharmaceuticals, LLC3$55
Vanda Pharmaceuticals Inc.2$55
Banner Life Sciences, LLC3$54
Abbott3$52

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$274,552 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$969,851
Medicare patients
607
Services billed
168,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4627$190,752
Avonex Pen (4 Pack)Interferon Beta-1a22$183,817
Radicava OrsEdaravone13$182,022
Kesimpta PenOfatumumab16$137,741
Gamunex-CImmune Globul G/Gly/Iga Avg 4646$130,876
BriviactBrivaracetam83$120,403
Nurtec OdtRimegepant Sulfate77$112,639
Dimethyl Fumarate13$72,409
EpidiolexCannabidiol (Cbd)18$66,672
BotoxOnabotulinumtoxina50$57,489
GocovriAmantadine Hcl15$54,922
Teriflunomide40$51,458
GammaplexImmun Glob G/Sorb/Gly/Iga 0-5013$42,557
TopamaxTopiramate23$32,439
XcopriCenobamate31$31,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$2,589$143,501106 claims
Grifols USA, LLCGamunex-C$82$130,87646 claims
PfizerNurtec Odt$574$112,63977 claims
AbbVieBotox, Ubrelvy, Qulipta$61,356$98,40285 claims
MDD US Operations, LLCGocovri$1,114$54,92215 claims
SK Life Science, Inc.Xcopri$1,708$31,47931 claims
Otsuka America Pharmaceutical, Inc.Rexulti$477$21,95216 claims
Amneal Pharmaceuticals LLCRytary$540$19,81821 claims
Sunovion Pharmaceuticals Inc.Aptiom$317$19,48916 claims
Eisai Inc.Fycompa$748$14,46212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Washington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →